Tyra Biosciences Statistics
Total Valuation
TYRA has a market cap or net worth of $1.15 billion. The enterprise value is $878.50 million.
Important Dates
The last earnings date was Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TYRA has 53.37 million shares outstanding. The number of shares has increased by 11.70% in one year.
| Current Share Class | 53.37M |
| Shares Outstanding | 53.37M |
| Shares Change (YoY) | +11.70% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 3.55% |
| Owned by Institutions (%) | 41.04% |
| Float | 17.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.09 |
| P/TBV Ratio | 4.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.71, with a Debt / Equity ratio of 0.02.
| Current Ratio | 17.71 |
| Quick Ratio | 17.45 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -34.75% and return on invested capital (ROIC) is -24.04%.
| Return on Equity (ROE) | -34.75% |
| Return on Assets (ROA) | -23.08% |
| Return on Invested Capital (ROIC) | -24.04% |
| Return on Capital Employed (ROCE) | -44.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.86M |
| Employee Count | 60 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +39.88% in the last 52 weeks. The beta is 1.09, so TYRA's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | +39.88% |
| 50-Day Moving Average | 16.13 |
| 200-Day Moving Average | 11.91 |
| Relative Strength Index (RSI) | 67.69 |
| Average Volume (20 Days) | 520,786 |
Short Selling Information
The latest short interest is 4.38 million, so 8.20% of the outstanding shares have been sold short.
| Short Interest | 4.38M |
| Short Previous Month | 4.71M |
| Short % of Shares Out | 8.20% |
| Short % of Float | 24.56% |
| Short Ratio (days to cover) | 16.72 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -125.99M |
| Pretax Income | -111.68M |
| Net Income | -111.68M |
| EBITDA | -125.43M |
| EBIT | -125.99M |
| Earnings Per Share (EPS) | -$1.88 |
Full Income Statement Balance Sheet
The company has $274.92 million in cash and $5.92 million in debt, giving a net cash position of $269.01 million or $5.04 per share.
| Cash & Cash Equivalents | 274.92M |
| Total Debt | 5.92M |
| Net Cash | 269.01M |
| Net Cash Per Share | $5.04 |
| Equity (Book Value) | 280.51M |
| Book Value Per Share | 5.26 |
| Working Capital | 265.34M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$91.11 million and capital expenditures -$90,000, giving a free cash flow of -$91.20 million.
| Operating Cash Flow | -91.11M |
| Capital Expenditures | -90,000 |
| Free Cash Flow | -91.20M |
| FCF Per Share | -$1.71 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |